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Recently, a variety of physiologically based pharmacokinetic (PBPK) models have been developed for the essential element
manganese. This paper reviews the development of PBPK models (e.g., adult, pregnant, lactating, and neonatal rats, nonhuman
primates, and adult, pregnant, lactating, and neonatal humans) and relevant risk assessment applications. Each PBPK model
incorporates critical features including dose-dependent saturable tissue capacities and asymmetrical diﬀusional ﬂux of manganese
into brain and other tissues. Varied inﬂux and eﬄux diﬀusion rate and binding constants for diﬀerent brain regions account
for the diﬀerential increases in regional brain manganese concentrations observed experimentally. We also present novel PBPK
simulations to predict manganese tissue concentrations in fetal, neonatal, pregnant, or aged individuals, as well as individuals with
liver disease or chronic manganese inhalation. The results of these simulations could help guide risk assessors in the application of
uncertainty factors as they establish exposure guidelines for the general public or workers.
1.Introduction
As an essential element, manganese (Mn) is required for
normal function of the central nervous system (CNS) and
other tissues [1]. As with all other metals, manganese
toxicity can occur with excessive exposure. A variety of
clinical eﬀects are associated with manganese toxicity,
including manganism, a parkinsonian movement disorder
that primarily aﬀects dopaminergic and γ-aminobutyric
acid- (GABA-) containing mid-brain structures that control
motor functions [2]. More subtle eﬀects can also occur.
For example, workers exposed chronically to manganese can
develop changes in visual reaction time, hand steadiness,
and eye-hand coordination [3]. These neurotoxic syn-
dromes develop when either manganese intake is excessive
(e.g., following high-dose oral, inhalation, or parenteral
manganese exposure) or when hepatobiliary clearance of
this metal is impaired. This observation suggests that the
doseofmanganesedeliveredtotargetregionswithintheCNS
is the primary determinant for manganese neurotoxicity.
The U.S. Environmental Protection Agency’s (USEPA)
list of hazardous air pollutants includes manganese com-
pounds. The USEPA and health agencies in other countries
have raised concerns that chronic inhalation of low levels of
manganese in ambient air may pose a risk to public health
due to the possible accumulation of manganese in target
tissues [4]. These concerns prompted the USEPA to call for
a series of pharmacokinetic studies, as well as the devel-
opment of physiologically based pharmacokinetic (PBPK)
models for manganese as part of the testing requirements2 Journal of Toxicology
for the organometallic fuel additive methylcyclopentadienyl
manganese tricarbonyl (MMT, a registered trademark of
Afton Chemical Corporation) [5] .P a r tIo ft h i st w op a r t
series discussed the development of the USEPA’s Alternative
Tier II testing program for MMT that collected critical
pharmacokinetic data for manganese in rodents and non-
human primates [5]. All test reports and correspondence
related to the Alternative Tier 2 Testing for MMT can be
found in the Federal Docket Management System (FDMS)
at http://www.regulations.gov/ identiﬁed by docket number
EPA-HQ-OAR-2004-0074.
One objective of the MMT Alternative Tier 2 program
was to generate data to support the development of PBPK
models for manganese [5, 6]. Development of these models
represents an eﬀort that spans more than a decade. Key
pharmacokinetic data needed to support PBPK model
development and a paradigm for a tissue-dose-based health
risk assessment for manganese were initially described by
Andersen and coworkers [7] in 1999 and helped guide future
studies. Numerous animal experiments have subsequently
addressed many of the data gaps raised by Andersen and
coworkers [7]( r e v i e w e di n[ 5, 6, 8]). This manuscript
describes the development of a series of PBPK models for
manganese. Moreover, we provide a framework for their
application to risk assessment.
2.ManganesePBPK Models:Development
andStatus
The development of the PBPK models proceeded in a step-
wise, iterative fashion with increasing model complexity
being added at each step. Table 1 provides an overview of the
initial “ﬁrst generation” models developed for this research
program. The earliest dosimetry models were adapted from
pharmacokinetic models developed for zinc, copper, and
other essential metals that focused on dietary intake and
deﬁciency.Featuresofthesemodelsthatweredeemedimpor-
tant for manganese include features of these models that
were deemed important for manganese include the ability to
describe homeostatic control of an essential element under
normal and deﬁcient dietary conditions, and the use of
compartmental and linear exchange rates to distribute the
essential element into tissues and cellular compartments.
The earliest manganese models were used to quantitatively
test assumptions regarding the movement of manganese
from the rodent gastrointestinal tract (GIT) and liver [9]
and to ascertain the degree to which systemic and orally
derived manganese are handled similarly in the liver [10].
The resulting pharmacokinetic models accurately described
the decreased gastrointestinal (GI) manganese uptake and
increased hepatobiliary elimination that is seen with rising
levels of manganese in the diet.
Early eﬀorts also developed an initial framework for a
multicompartment PBPK model. These models evaluated
the kinetic behaviors of manganese in the brain, liver, and
respiratory tract during and after manganese inhalation [12,
13]. Several model structures were considered during this
developmentalphase(Table 1).Ultimately,manganesekinet-
ics were best described using a model that included dose-
dependent saturable tissue binding as well as free and bound
manganese [13]. In this context, bound manganese was
conﬁned to tissues and reﬂected basal manganese concentra-
tions. Free manganese circulates in the blood and increasing
concentrations resulted during manganese inhalation. Free
manganese was rapidly cleared following exposure, thereby
returning tissue manganese concentrations to their original
basal levels. This rise of free brain manganese concentration
was described with diﬀusion rate constants (kin and kout).
Peak tissue manganese concentrations were constrained by
the tissue maximal binding capacity (Bmax). Importantly,
dose dependencies predicted by the Nong model [13]w e r e
consistent with the total manganese tissue levels measured in
rats following manganese inhalation. The model also repli-
cated the rapid increases in tissue manganese concentrations
seenatthehighestinhaledmanganeseconcentrations,aswell
as the rapid return to baseline after exposure ceased. The
model developed by Nong and coworkers [13] for the adult
rat incorporated these and other features and was used as the
basis for all subsequent “second generation” animal PBPK
models (Table 2).
Starting in 2009, the focus of the modeling eﬀort
began to shift to the development of more complete PBPK
models for animals (Table 2). These models retained many
of the features found in the Nong model [13], including
dose-dependent saturable tissue capacities and asymmetrical
diﬀusional ﬂux of manganese into various tissue compart-
ments. The second generation models also used airway
deposition models based on particulate aerodynamics to
describe manganese delivery to the respiratory tract [17].
Descriptions of the upper airways were broadened to include
descriptions of the nasal cavity and olfactory epithelium
using data published by Schroeter et al. [18]. Regarding
the CNS, separate compartments for the olfactory bulb,
striatum, pituitary gland, and cerebellum were developed.
Speciﬁc inﬂux and eﬄux diﬀusion rate constants (kin, kout)
and binding constants (Bmax, ka, kd)f o rd i ﬀerent brain
regions were used to account for the diﬀerential increases
in regional brain manganese concentrations seen under
various experimental conditions. These modiﬁcations led
to the publication of the revised adult rat model depicted
in Figure 1 [14]. Additional models were subsequently
developed to describe lactational [15] and gestational [16]
transfer of manganese in rats. In all cases, model output
was compared to inhalation data obtained under this test
program and that from the available literature.
In 2009, Nong and coworkers also described the devel-
opment of a PBPK model for nonhuman primates from
the revised adult rat model [14]. The monkey PBPK model
was viewed as a critical step in the evolution of appropriate
human models (Figure 2). One goal of the modeling eﬀort
was to retain as many features present in the rat model as
possible. Body weight, tissue volumes, olfactory and respira-
tory tissues surface areas, ventilation rates, blood ﬂows, and
certain other model parameters were adjusted to describe
monkey physiology while others (biliary clearance and brain
diﬀusional ﬂuxes) were allometrically scaled based on bodyJournal of Toxicology 3
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Figure 1: The PBPK model structure developed by Nong and coworkers [14] describing tissue manganese kinetics in adult rats. The overall
PBPK model structure is shown in (a); an expanded view of the respiratory tract modeling is shown in (b). Inhaled manganese is absorbed
through deposition of particles on the nasal and lung epithelium. Most of the manganese deposited in the nasal cavity is absorbed into the
systemic blood while a small fraction undergoes direct delivery to the olfactory bulb. Every tissue has a binding capacity, Bmax,w i t ha ﬃnity
deﬁned by association and dissociation rate constants (ka, kd). Free manganese moves in the blood throughout the body and is stored in
each tissue as bound manganese. Inﬂux and eﬄux diﬀusion rate constants (kin, kout)a l l o wf o rd i ﬀerential increases in manganese levels for
diﬀerenttissues.Qp,Qc,Qtissue refertopulmonaryventilation,cardiacoutput,andtissuebloodﬂows.Reprintedfrom[14](withpermission).
weight. Tissue-speciﬁcbinding capacities werescaled to their
respective tissue volumes while tissue-binding rate constants
(ka and kd) were nearly constant from rat to monkeys.
Dietary uptake and basal biliary excretion rates were also
adjusted to ﬁt measured background tissue manganese
concentrations.
The ﬁnal steps in the modeling program were to develop
PBPK models for humans (Table 3). The starting point
for this eﬀort was the monkey PBPK model developed by
Nong et al. [14] with appropriate changes in physiological
descriptions, allometric scaling of biliary clearance and brain
diﬀusional ﬂuxes to body weight, and small changes in tissue6 Journal of Toxicology
Adult rat
model
model
model
Adult monkey
Adult human
   Human 
gestation and
lactation
models
Rat
gestation and
lactation
models
Figure 2:Parallelogram approach fordeveloping MnPBPKmodels
for adult humans, as well as gestation and lactation.
binding rate constants (ka and kd). A signiﬁcant change
in the model involved the use of a more physiological
description of the GIT to address an apparent delay in
GI absorption evident in tracer Mn studies in primates
[19] and the diﬀerential enterocyte turnover rates across
lifestages[20].Schroeterandcoworkers[19]includedaseries
of gut compartments (e.g., GI lumen and epithelium) to
better describe the absorption of ingested manganese and
storage of this metal. The epithelial linings of the small and
large intestine have a high cellular turnover and contain
rapidly proliferating cells (enterocytes) which replace those
that are shed into the lumen. Enterocytes are an important
site for metal uptake and ultimately excretion through the
sloughing of these cells. In our model, manganese transfer
from the upper GIT epithelium to the lower GIT resulted
from sloughing of enterocytes from the epithelial layer. The
manganesefoundinshedenterocyteswasultimatelyexcreted
into feces without entering the systemic circulation. This
allowed for the diﬀerential rates of enterocyte sloughing
f o u n di nd i ﬀerent life stages to be accounted for [19, 20].
The fraction of manganese absorbed by the GIT (Fdietup)
andthebiliaryexcretionrateconstant(kbileC)w er ecalibrat ed
based on steady-state tissue concentrations and 54Mn tracer
studies. Induction of biliary elimination of manganese was
alsoincludedinthemodel.Thesechangesinmodelstructure
were suﬃcient to capture the observed dose-dependent
changes in manganese absorption by the GIT and biliary
excretionbythehepatobiliarysystem.Schroeterandcowork-
ers [19] used a step-wise approach to model development by
ﬁrst developing a revised monkey PBPK model, followed by
an adult human model, which was validated by the available
h u m a nM nt r a c e rd a t a[ 19]. The ﬁnal step in the modeling
eﬀorts culminated in the development of a model that
described gestational and lactational transfer of manganese
in humans [20].
3. PBPKModelsinManganeseRiskAssessment:
Why Tissue Dose Matters
As an essential metal, manganese is found in all mammalian
tissues. Several homeostatic mechanisms have evolved to
tightlyregulatethesetissuemanganeseconcentrationswithin
a normal range of values. For most tissues, normal man-
ganese concentrations in humans range from 0.15 to
4μgMn/g of wet tissue [1]. As noted earlier, manganese neu-
rotoxicity occurs when manganese intake exceeds elimina-
tion, resulting in manganese accumulation in brain regions
including the globus pallidus, which is particularly sensitive
to manganese accumulation during overexposure. Although
manganese neurotoxicity is sensitive to exposure dose, it is
relatively insensitive to route of exposure, as similar neuro-
logical responses have been linked to prolonged high-dose
manganese inhalation, drinking water ingestion, long-term
total parenteral nutrition (TPN), or impaired manganese
clearance because of hepatobiliary dysfunction [24]. Because
oftheubiquitousnatureofmanganeseandtheroleofdietary
manganese in establishing steady-state tissue concentrations,
risk assessments of inhaled manganese should consider the
essentiality of manganese from diet to establish the tissue
concentrations that will be altered with increasing levels of
inhaled or ingested manganese. Therefore, to understand the
risk to humans from excessive manganese exposure, it is
important to determine the exposure conditions that result
in manganese concentrations in the brain that are increased
signiﬁcantlycomparedwithbrainmanganeseconcentrations
arising from normal dietary intake [7]. Pharmacokinetic
models can be used to help establish safe exposure levels by
predicting exposure conditions that lead to toxicologically
signiﬁcant increases in tissue manganese.
4. Application of PBPK Models in
HumanHealth Risk Assessment
One of the ﬁrst attempts at applying PBPK models in scenar-
ios relevant to human health risk assessment was performed
by Schroeter and colleagues [19]. These investigators used
their PBPK model to predict brain manganese concentra-
tions in monkeys and people following subchronic man-
ganese inhalation (Figure 3). The predicted globus pallidus
manganese concentrations for monkeys (Figure 3(a))c o m -
pared favorably with those observed by Dorman et al. [21]
in monkeys subchronically exposed to manganese sulfate
(MnSO4), giving added conﬁdence that the PBPK models
were designed and parameterized appropriately. The human
simulations performed by Schroeter mimicked an 8hr/day
5 day/week occupational exposure. The larger magnitude
changes predicted in monkeys compared with humans at
higher inhalation exposure concentrations may be due to
saturation of manganese binding sites in the monkey at the
higher manganese concentrations in the diet. Human diets
are typically low in manganese content compared to diets
in laboratory animal chows, which are often supplemented
to much higher (∼100ppm) levels. At the lowest human
exposure concentration used in our simulations (0.001mg
Mn/m3), the model predicted no appreciable increase (<1%
change from basal concentrations) in human globus pallidus
manganese concentrations above the background levels
associated with normal dietary exposure (Figure 3(b)). At an
exposure concentration of 0.01mg Mn/m3, slight increasesJournal of Toxicology 7
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Figure 3: Curves showing simulated end-of-exposure brain tissue manganese concentrations in monkeys (a) and people (b) as a function of
inhalation exposure concentration (mg Mn/m3). Simulated exposures are for 90 days (5 days/week) for either 6h/day (monkeys) or 8h/day
(human beings). The monkey simulation results at 1.5mg/m3 (a) are compared with data from Dorman et al. [21] depicted with symbols
showing means and standard errors (SEs) from four to six monkeys per time-point. The larger magnitude changes predicted in monkeys
compared with humans at higher inhalation exposure concentrations could be due to the saturation of manganese binding sites in the
monkey coming from higher manganese concentrations in the diet of the monkeys. Modiﬁed from [19].
(∼5%) in globus pallidus manganese concentration above
background levels were predicted during the inhalation
exposure period. More signiﬁcant (>30%) increases in
globus pallidus manganese concentrations were predicted
at the higher exposure concentrations (>0.1mg Mn/m3).
These data are consistent with derivations of benchmark
concentrations for subclinical neurological eﬀects from
occupationalstudiesatconcentrationsof0.2mgMn/m3 [25]
and indicate that signiﬁcant increases in tissue manganese
concentration above normal background variability are
required for subclinical eﬀects to be manifested.
In light of our success in describing the rat and monkey
tissue data and concordance with human responses and
speciﬁc exposures, we conducted additional simulations
using the available PBPK manganese models identiﬁed in
Tables 2and3toaddressotherexposurescenariosofconcern
to toxicologists and risk assessors. Our goal was to predict
tissue concentrations in individuals with altered physiology
due to developmental life stage (Scenario 1) or disease
(Scenario 2). A second goal was to use the PBPK models
to predict brain manganese concentrations with prolonged
inhalation exposure and variable dietary manganese intake
(Scenario 3). The results of these simulations could help
guide risk assessors in the application of intra- or inter-
species uncertainty factors (UFs) as they establish exposure
guidelinesforthegeneralpublic(e.g.,aninhalationreference
concentration or RfC) or workers (e.g., threshold limit value
or TLV). In most risk assessments, UFs are applied to
lower the acceptable air concentration to protect potentially
susceptible subpopulations or account for species diﬀerences
in response. For example, the current US EPA manganese
RfC derivation incorporates a composite UF of 1000 that
included UFs of 10 to protect sensitive individuals, 10 for
use of a LOAEL, and 10 for database limitations, such as less
than chronic periods of exposure, inadequate information
regarding developmental and reproductive toxicity, and
uncertaintyaboutthetoxicityofvariousformsofmanganese
[26].
The alternative PBPK model-based approach we present
in this manuscript results in the development of pharma-
cokinetic chemical-speciﬁc adjustment factors (CSAFs) (or
data-derived extrapolation factors (DDEFs)) that could be
used in lieu of default UFs used in most risk assessments
[27, 28]. A pharmacokinetic CSAF is a ratio in humans or
animals of a measurable metric for internal exposure to the
active compound such as area under the curve (AUC) (AUC
is a surrogate for the daily and/or cumulative manganese
dose received by an individual), Cmax, or clearance between
a baseline and potentially susceptible subpopulation [27].
While serving the same purpose as UFs, these extrapo-
lation factors are based on data directly pertinent to the
chemical of interest, rather than having their basis on
default assumptions about inter- and intraspecies variability
[28]. This approach leads to a higher conﬁdence in the
calculated adjustment factor and contributes to consistency
in regulatory processes and decisions [28]. Unless otherwise
noted, all simulations in these scenarios provide results for
total tissue manganese concentration.
Scenario 1. Consideration of Potentially Susceptible Subpopu-
lations Based on Lifestage and Pregnancy Status. Age-related
changes in physiology can inﬂuence the pharmacokinetics of
xenobiotics, and some experimental data suggest that that
the aged nervous system may be at increased risk following8 Journal of Toxicology
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Figure 4: Simulated olfactory bulb (L) and striatum (R) manganese concentrations in adult and aged (16 month old) male rats following
6hr/d inhalation MnSO4 exposure at 0.5mg Mn/m3 for 90 days. Model simulations for aged rats had a 25% decrease in minute volume
consistent with reported reduction in pulmonary function [22, 23].
exposure to manganese. For example, manganese-induced
d e p l e t i o no fs t r i a t a lg l u t a t h i o n ei sm o r es e v e r ei na g e d( 2 0
monthsold)ratsthaninyoung(3-month-old)ratsfollowing
repeated (7 day) high-dose (15–100mg Mn/kg/day) oral
exposure to manganese chloride [29]. Occupational and
environmental exposure studies indicate that increased age
may be a risk factor for manganese-induced neurobehavioral
deﬁcits[30].Toexplorethis questionmorequantitatively, we
used the rodent PBPK model, as data were available in the
literature regarding the degree to which pulmonary function
declines with age.
Model simulations for aged rats (Figure 4) used a 25%
decrease in minute volume consistent with reported reduc-
tion in pulmonary function in aged rats [22, 23]. Aged rats
had lower target brain tissue manganese concentrations than
middle-aged animals at the same exposures. This diﬀerence
is likely due to the decreased breathing rates and pulmonary
capacity of aged animals [31]. Since the manganese tissue
concentration in the potentially susceptible subpopulation
was less than in adult males, a pharmacokinetic CSAF for the
aged life stage should be <1. Extending this simulation from
ratstohumanswillrequiresomechangestothephysiological
parametersusedinthecurrentmodels.Forexample,changes
in liver volume and hepatic blood ﬂow that signiﬁcantly
impact xenobiotic metabolism and clearance occur in geri-
atric human patients [32]. Likewise, aged humans have
altered biliary [33], pulmonary [34], and gastrointestinal
[35] function that may alter manganese pharmacokinetics.
These complexities require a human model simulation of
this scenario that lies outside of the focus of the present
manuscript. However, we have provided the template for
generating a pharmacokinetic CSAF for aged individuals.
This preliminary analysis indicates that large adjustment
factorsmaynotbenecessarytoextrapolatefromadultmales,
which typically are the subject of the occupational epidemi-
ological studies that determine the point of departure in
manganese risk assessments, to aged life stages.
Evaluation of other life stages is also important since
theyarealsocoveredintheextrapolationsfromoccupational
studies by UFs. Epidemiological studies in children have
reported an association between elevated dietary manganese
exposure and neurobehavioral and neurocognitive deﬁcits
[36]. Concerns for potential vulnerability to manganese
neurotoxicity during fetal and neonatal development have
been raised by regulatory agencies [37]. PBPK models
developed for this program can be used to quantitatively
estimate the role that higher intestinal absorption of ingested
manganese and a lower basal biliary excretion rate seen in
children (see [1]f o rr e v i e w )a ﬀect dose-to-target-tissue dur-
ing manganese inhalation. To this end, Yoon and coworkers
[20] used their human PBPK model to estimate average
expected daily AUCs for the globus pallidus among diﬀerent
life stages (nonpregnant, pregnant, and lactating women,
fetuses, nursing infants, and 3-year-old children) for three
diﬀerent exposure conditions, namely, 0, 0.001, and 0.01mg
Mn/m3 for 24hr/day 7 day/week (see [20], Figure 7). Ex-
posure durations in the diﬀerent simulations varied with life
stage (∼9 month pregnancy for women and their fetuses;
4 months for nursing infants and their mother, and 3 years
after birth for children). The average daily AUC to the
globus pallidus was calculated at the end of each simulation
after running the model for appropriate durations for the
selected life stages. Pregnancy and lactation did not greatly
aﬀect the simulated internal dose of Mn in the brain.Journal of Toxicology 9
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Figure 5: Simulated globus pallidus manganese concentrations in humans following inhalation exposure to MnSO4 at 0.00005 (a) or 0.2mg
(b) Mn/m3 for 8hr/d, 5d/wk, for one year. Simulations were performed using the human model developed by Schroeter et al. [19] with
the following exceptions: model simulations for humans with hepatobiliary impairment had a 50% decrease in liver blood ﬂow and a 50%
decrease in biliary excretion (KbileC) to simulate moderate hepatobiliary disease (see text for more details).
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Figure 6: Distributions (min, 5th, med, 95th and max) of globus
pallidus concentrations simulated for a human population with
the input distributions described in Scenario 3 (see text for more
details). Comparison of steady-state brain manganese concentra-
tion following 365 days of continuous exposure (24hr/7 days).
There is an overlap of tissue Mn levels between inhaled exposure
and dietary variability. Changes in globus pallidal manganese
concentrations from exposures <0.05mgMn/m3 are small when
compared to the impact of normal dietary variation.
The average daily AUCs were greater in men than in women
at high-dose environmental exposure of Mn, that is, expo-
sures where brain Mn concentration started to rise from the
basal level. The change in the average daily globus pallidus
AUC resulting from high-dose manganese inhalation was
greater in nursing infants compared to other life stages
due to the lower (marginally deﬁcient) basal levels of tissue
manganese at this age [20]. For example, the estimated
average AUC in the highly exposed infants was approx-
imately 11.5μgMn·hr/g/day compared to approximately
7.9μgMn·hr/g/day in unexposed infants, while the AUC
in the adult males increased from 9.3μgMn·hr/g/day to
11.5μgMn·hr/g/day. This apparent increase in sensitivity
toward increasing tissue concentration is due to the lower
basal tissue levels in neonates and likely represents the
enhanced demand for manganese during this life stage [20,
38]. Both in adults and children after weaning, the relative
contribution of inhalation (0.01mg/m3) was smaller than
their normal dietary intake at these inhalation exposures.
Because no life-stage achieved a higher AUC than adult
males, the PK simulations support a pharmacokinetic CSAF
of 1 for fetal, neonatal, pregnant, and nonpregnant female
life-stages.
Scenario 2. Consideration of Individuals with Moderate-to-
Severe Hepatobiliary Dysfunction. Individuals with severe
hepatobiliary disease often develop elevated brain man-
ganese concentrations when compared with normal individ-
uals [39]. For example, Rose and coworkers [39]r e p o r t e d
brain manganese concentrations in autopsy samples taken
from patients with liver cirrhosis. When compared to
age-matched controls, cirrhotic patients had signiﬁcantly
elevated brain manganese concentrations. These increases
were most marked in the globus pallidus, where patients
with severe cirrhosis had mean (±SEM) pallidal manganese
concentrations of 4.04 ± 1.54μg/g versus 1.41 ± 0.91μg/g in
controls. Rose and coworkers [39] also examined whether
rat models using an end-to-side portacaval anastomosis orJournal of Toxicology 11
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Figure 7: Simulated end-of-exposure nonhuman primate globus
pallidus manganese concentrations following a 24h/d, 7d/wk
inhalation for either 90 days (subchronic) or 2yr (chronic)
exposure to MnSO4. These simulations indicate that globus
pallidus manganese concentrations are expected to rapidly reach
pseudosteady-state levels during high dose manganese exposure,
and that duration of exposure has a minimal eﬀect. Its contribution
only occurs once exposures reach the threshold to cause tissue
accumulation.
an intracholedochal injection of formalin and concomitant
ligation of the bile duct to create an experimental model of
biliarycirrhosiscouldmimictheseﬁndings.Asexpected,rats
with biliary cirrhosis or a portacaval-shunt had increased
pallidal (increased by 27% to 57%) and caudate/putamen
(increased by 57 to 67%) manganese concentrations when
compared with sham operated or normal control groups. It
is important to note that the humans and animals studied
by Rose had signiﬁcant clinical liver disease. For example,
the cirrhotic patients studied by Rose et al. [39] died of an
extreme form of hepatic encephalopathy (i.e., hepatic coma).
Individuals with liver or biliary cirrhosis can also
develop signiﬁcant changes in hepatic blood ﬂow that may
aﬀect manganese pharmacokinetics. Annet and cowork-
ers [40] reported that patients with chronic liver disease
of various grades (i.e., Child-Pugh classes A, B, and
C )h a dm e a n( ±SD) apparent liver perfusion rates of
36.29 ± 17.96mL/min/100mL liver volume versus 65.22 ±
24.73mL/min/100mL liver volume in patients without liver
cirrhosis (as measured using magnetic resonance imaging).
An approximately 50% reduction in total hepatic blood
ﬂow has been seen in dogs with side-to-side or end-to-
side portacaval anastomoses [41]. Other investigators have
reported signiﬁcant (∼50%) reductions in hepatic blood
ﬂow in rats with common bile duct ligation [42]. A similar
observation is also seen in people with hepatic cirrhosis [43].
These studies indicate that there should be a 50% reduction
in hepatic blood ﬂow in the PBPK model parameters for
consistency with the observations of experimentally induced
hepatobiliary dysfunction.
Impaired secretion of bile acids, bilirubin, and other
organic anions, consistent with reduced biliary function, is
also observed in liver disease [44]. For example, rats with
mild hepatic stenosis have an approximate 15% reduction
in basal bile ﬂow when compared with control animals
[45]. One animal model in which biliary function has
been quantitatively examined is liver dysfunction induced
by the subchronic to chronic administration of TPN, an
intravenous diet given in severe cases of GI disorders. Das
et al. [46] reported that rabbits receiving TPN will develop
qualitatively similar decreases in bile ﬂow (reduced by 60%),
bile acid secretion (52%), and sulfobromophthalein (BSP)
excretion(38%)whencomparedwithcontrolanimals.These
animals also developed hepatocellular degeneration and
portal tract inﬂammation. Thus, the available data support
using a 50% reduction in bile ﬂow in the PBPK model
simulation.
In this study, we used the Schroeter et al. [19]m o d e l
to simulate globus pallidus manganese concentrations in
humans following a one year inhalation MnSO4 expo-
sure to either 0.00005 (the USEPA RfC) or 0.2mg (the
current ACGIH TLV) Mn/m3 for 8hr/d, 5d/wk. Model
simulations for people with hepatobiliary impairment had
a 50% decrease in liver blood ﬂow and a concomitant
50% decrease in biliary excretion (KbileC) consistent with
changes reported in people and/or animals with liver disease
as discussed above. The simulations show that, regardless
of inhalation concentration, the model predicted higher
pallidal brain manganese concentrations due to hepatic
dysfunction alone (Figure 5), which was expected based on
available data. Inhalation at the RfC had no signiﬁcant
eﬀect on pallidal concentrations, regardless of hepatobiliary
function (Figure 5(a)). Inhalation concentrations at the TLV
produced an increase in end-of-exposure pallidal manganese
concentrations that were in addition to the increase from
hepatobiliary disease (approx. 0.85μg/g versus 0.68μg/g
in controls, Figure 5(b)). A CSAF of ∼1.25 (0.85/0.68)
is supported by the PBPK modeling for this extremely
sensitive subgroup. Since this CSAF value was determined at
occupational exposure levels, and no changes were observed
at the RfC, this disease-related CSAF is likely conservative
for environmental exposures which do not cause tissue
accumulation.
Scenario 3. Consideration of Dietary Mn Variability and
Chronic Manganese Inhalation. The strengths of using PBPK
models in risk assessment include the ability to use the
models to examine both dietary and inhaled intakes and
support extrapolations from high to low doses, across routes,
for diﬀerent animal species, and for durations of exposure
longer than those used in the studies that the models were
based on [47]. To date, the most complete pharmacokinetic
datasets for inhaled manganese available for PBPK model
development and validation were developed for rats and
monkeys using exposure durations of up to 90 exposure
days (typically 6hr/day, 5days/week, reviewed in [5]). The
manganese PBPK models described in this manuscript can
be used to extrapolate beyond these exposure conditions.12 Journal of Toxicology
This scenario demonstrates this ability by predicting globus
pallidus manganese concentrations in people following a
continuous(24hr/day)chronic(1year)manganeseexposure
(Figure 6).
The monkey PBPK model developed by Nong et al. [14]
scaled to humans was used to simulate globus pallidus man-
ganese concentrations in people while varying the dietary
intake. Normal variation of manganese concentration in
globus pallidus due to the ﬂuctuation in daily dietary expo-
sure was simulated in an adult human population of 10,000
using Monte Carlo techniques. These simulations varied
the daily dietary intake of manganese using published data
(mean [±SD]: 2.43 ± 1.8mg/day; range 0.07–6.2mg/day)
[48]. Published distribution values (mean) were used for
body weight (70kg), tissue volumes (as % body weight) for
blood (8%), bone (12%), brain (2%), liver (3%), lung (1%),
andtheremainderofthebody(0.74%)[49,50].Distribution
values (mean) for tissue blood ﬂow (as % cardiac output)
for bone (4%), brain (11%), liver (23%), and nose (1%)
were also used [49, 50]. The coeﬃcient of variation used
for body weight, tissue volume, and blood ﬂow parameters
was 0.30. Mean values for cardiac output and pulmonary
ventilationweresetat13L/hr/kgand20L/hr/kg,respectively.
Ac o e ﬃcient of variation used for these parameters was 0.50.
All parameter distributions were truncated by two standard
deviations and statistical correlations of parameters were
not included in our analysis. Air manganese concentrations
ranged from current USEPA RfC (0.00005mg Mn/m3)t o
0.5mg Mn/m3, a concentration that represents potential
occupational exposure levels, although with continuous
exposure in this case.
A second question that we wanted to explore is the eﬀect
of exposure duration on the rate at which globus pallidus
manganese concentrations change following manganese
inhalation. Here, we compared the end-of-exposure tissue
concentrations of a subchronic (90-day) versus 2-year expo-
sure duration with the nonhuman primate model (Figure 7).
Globus pallidus manganese concentrations rapidly reach
pseudosteady state levels during high dose manganese expo-
sure. These simulations are in accord with observations
reported by Dorman and coworkers [21]w h or e p o r t e d
that rhesus monkeys exposed (5 d/week) for 15, 33, or
65 exposure days to MnSO4 at 1.5mg Mn/m3 developed
mean (±SEM) globus pallidus manganese concentrations of
1.92 ± 0.40, 2.41 ± 0.29, and 2.94 ± 0.23μgM n / gt i s s u e
wet weight, respectively, all of which were signiﬁcantly
diﬀerent (P<0.05) than background tissue levels of 0.48 ±
0.04μgMn/g tissue wet weight. Extending the simulation to
2 years produced a very slight leftward shift of the exposure-
accumulation curve, but it did not change the threshold
for tissue accumulation. For example, at 0.2mg MnSO4/m3
(the current ACGIH TLV), a pharmacokinetic CSAF for
subchronic to chronic duration is 1.06. Once exposure
passes the threshold for tissue accumulation, a PK CSAF for
duration of exposure is maximally 1.1.
Results of these simulations show several important
ﬁndings. Brain manganese concentrations are controlled
over a wide range of low-to-moderate exposure conditions
at and above typical environmental exposures. Due to
homeostatic controls, changes in globus pallidal manganese
concentrations from exposures that exceed the current RfC
even by several orders of magnitude (0.05mg Mn/m3)a r e
small when compared to those seen as a result of normal
variation in the dietary intake of manganese as demon-
strated by the Monte Carlo analysis of dietary variation
(Figure 6). However, once these homeostatic mechanism(s)
are overwhelmed, pallidal manganese concentrations rise
rapidly. The threshold for this response appears to occur at
approximately 0.001–0.01mg Mn/m3 (Figure 7).
5. FutureApplications of PBPK Models
The scenarios that we have explored here can easily be
broadened to address other concerns raised in relation to
the human health risk assessment of manganese. Another
scenario that may prove useful to risk assessors is a consider-
ation of the eﬀect of altered iron homeostasis on manganese
pharmacokinetics, since iron deﬁciency and iron-deﬁcient
anemia exist worldwide [51]. Inadequate tissue iron status
resulting from dietary iron deﬁciency or anemia can lead to
altered brain manganese deposition in animals [52–54]. It is
unknown whether interactions between iron and manganese
for divalent metal transporter 1 (DMT1) and other shared
cellular membrane metal transporters account for this eﬀect
[55,56].Oncethesepathwaysandinteractionsaremorefully
elucidated, especially with quantitative measurements, these
features can be incorporated into the existing PBPK models.
Although the PBPK models were originally created to
support the risk assessment of combustion products of
the fuel additive MMT (see [5]), they have much broader
application to toxicologists and risk assessors. PBPK models
can consider the impact of particle size and solubility on
manganese dosimetry, especially as it relates to nanoma-
terials. Manganese nanoparticle exposure may occur dur-
ing occupational exposure scenarios, potentially including
welding. Nanoparticles display several curious inhalation
pharmacokinetic behaviors that may be independent of
chemical form [57]. For example, inhaled nanomaterials are
deposited extensively in the nasal cavity [58]; in addition,
a large percentage (∼75%) of the nanomaterials that reach
the alveolar region remain at that site, with less than 5%
of inhaled nanoparticles translocating out of the lungs [59];
charged nanoparticles are more likely to travel to the brain
via axonal transport within the olfactory nerve than are
neutral nanoparticles [60]; and nanoparticle size also inﬂu-
ences organ distribution and renal excretion [61, 62]. Several
PBPKmodelshavebeendevelopedfornanoparticles[11,62–
64]. These models were parameterized and validated using
experimental pharmacokinetic data collected for diﬀerent
nanomaterials (e.g., iridium, silver, or technetium-labeled
carbon nanoparticles) using data obtained from rats or
humans. There is only sparse data on the pharmacokinetics
of manganese-based nanoparticles. Some work examined
translocation of manganese oxide (MnO2) nanoparticles
from the nasal cavity to the brain [65]; however, these
investigators relied on the use of nasal instillation rather
than inhalation. Elder and coworkers [66]e x p o s e dr a t st oJournal of Toxicology 13
MnO2 nanoparticles with individual aerodynamic diameters
of 3–8nm (note these particles form ∼30nm agglomerates
in the exposure system) for 6hr/day, 5 days/wk, for a total
of 12 inhalation exposure days. In this study, the olfactory
bulb showed the greatest changes in proinﬂammatory gene
expression when compared to the midbrain, striatum, and
other brain regions. This ﬁnding supports the conclusion
that inhaled manganese nanoparticles, like larger particles,
can undergo olfactory transport from the nasal cavity to
the olfactory bulb. However, PBPK modeling in rodents
and MRI analysis in primates have demonstrated that the
olfactory pathway does not appear to signiﬁcantly impact
manganese delivery to tissues outside of the olfactory path-
way [67, 68]. While research on manganese nanoparticles is
still limited, there is some evidence that soluble manganese
m a yb em o r eb i o a v a i l a b l ea n dc a u s em o r ee ﬀects relative
to equivalent amounts of nanoparticle manganese. Whereas
most of the deposited nanomaterial appears to stay in the
lung, soluble manganese is readily bioavailable [14, 59,
69]. Furthermore, manganese nanoparticles appear to be
less toxic than an equivalent dose of soluble Mn2+.D a i l y
intratracheal instillation of soluble MnCl2 in rats for 3–6
weeks led to increased brain manganese levels, a reduction
in body weight gain, and a decrease of open ﬁeld motility
when compared to controls, whereas the equivalent dose of
MnO2 nanoparticles had no signiﬁcant eﬀects [65]. Also,
MnO2 nanoparticles were less toxic to PC-12 cells in vitro by
the MTT assay than an equivalent dose (in ug/mL) of soluble
Mn acetate [70]. Thus, the current PBPK modeling, based
on soluble manganese (MnSO4), may represent a worst-case
scenario relative to nano-manganese after accounting for
diﬀerences in pulmonary deposition. This expectation will
befurtherclariﬁedasmoredatabecomeavailablecomparing
the pharmacokinetics and pharmacodynamics of nano- and
soluble manganese.
Another potential application of the manganese PBPK
models for risk assessment is the evaluation of the literature
on the neurological outcomes of manganese exposure in
primates, potentially identifying tissue concentrations that
lead to adverse eﬀects. This assessment would allow the
models to explore the pharmacodynamic aspects of Mn
exposure. The models could then be used to select the
most appropriate dose metric for establishing a point of
departure in future risk assessments. A previous attempt to
evaluate dose response for the eﬀects of Mn in experimental
animals [71] relied on estimated cumulative intake of Mn
as the only measure for comparison across studies with
diﬀerent doses, durations, and exposure routes. Alternative
toxicologically relevant dose metrics, including estimated
peak concentration, average concentration, and cumulative
dose (i.e., AUC) during the Mn exposure period could be
estimated using a PBPK model known to accurately account
for dose dependencies of Mn distribution in the monkey
for combined inhalation and dietary exposures. A large
nonhuman primate response literature exists for analysis,
including exposures by inhalation, oral, intraperitoneal,
and subcutaneous dose routes, and spanned durations
u pt o2y e a r s[ 71]. This type of analysis using PBPK
models is currently underway and will make it possible
to provide a consistent description of the dose response
relationship for the eﬀects of Mn independent of exposure
route.
Finally, PBPK models may be used in an alternative
dosimetric-based risk assessment strategy for essential ele-
ments considering dietary intake, natural tissue background
levels, and dietary and population variability. An upper safe
exposure value could be based on an air concentration that
changes brain tissue levels by no more than some fraction
of the normal variability within a healthy population [7,
72]. The relationship between exposure levels and target-
tissue levels would be determined by the use of PBPK
models, which would account for the existence of the dose-
dependent transition (i.e., threshold level) for accumulation.
This methodology is inherently conservative with respect
to neurological outcome, as the air guideline would be set
to prevent only tissue accumulation. Potentially sensitive
subpopulations as described in the scenarios here can be
quantitatively taken into account with PBPK modeling
insteadoftheapplicationofUFsasdescribedinthescenarios
here. Another key advantage of a pharmacokinetic approach
for risk assessment is that it is not reliant upon existing
occupational studies, which have limitations with respect
to exposure assessment, evaluation of adverse eﬀects, and
establishing causation (reviewed in [30]), to establish a point
of departure [72]. Similar PBPK model-based dosimetry
approaches should also be considered for risk assessments
with other essential metals, such as copper and zinc.
However, the development of a comprehensive PBPK model
for any essential element depends on the availability of a
suﬃciently diverse and robust data set to enable model
construction and validation. These data now exist for Mn,
due in large part to the Alternative Tier 2 testing program for
MMT [5].
6. Conclusions
The development of PBPK models facilitates more rigorous
quantitative analyses of the available pharmacokinetic data
and allows the comparison and consideration of dose to
target tissue in risk assessment decisions. While PBPK
modeling for many exogenous compounds has become
routine, there are signiﬁcantly more challenges in under-
standing the full set of biological factors that control uptake,
distribution, and clearance of manganese and other essential
nutrients that exert toxicity at high doses. An overarching
goal of our modeling eﬀorts was to evaluate situations that
may lead to increased brain accumulation due to altered
manganese regulation in healthy and potentially susceptible
human populations. These subpopulations, identiﬁed as
part of the Alternative Tier 2 testing program for MMT,
include adult males, females, the aged, fetuses, neonates,
and pregnant women, as well as those with high or low
dietary manganese intake. Pharmacokinetic CSAFs were
calculated to extrapolate from adult males, which are
the typical subjects evaluated in occupational manganese
studies, to these other life stages. These values were all ≤1,
indicating that no pharmacokinetic adjustment is needed14 Journal of Toxicology
to account for these populations. Regarding duration of
exposure, a CSAF of 1 to 1.1 is calculated depending on
the inhalation concentration once exposure levels increase
above the threshold for tissue accumulation (i.e., 0.001–
0.01ug/m3). In addition, while diseased individuals are not
typicallyincludedintheextrapolationsdoneintypicalhealth
risk assessments of environmental exposure, we have now
extended the simulations to include those with moderate to
severe hepatobiliary insuﬃciency to represent a population
at a higher risk of manganese eﬀects. The simulations
suggest that an impaired individual may have elevated
brain manganese concentrations regardless of manganese
inhalation levels, and typical environmental levels do not
increase this burden. At higher exposure levels, a CSAF of
1.25 is derived for the extremely sensitive subgroup. In total,
the pharmacokinetic CSAFs developed here are less than
the pharmacokinetic portion of the typical UF of 10 for
human variability incorporated in current risk assessments
of ambient manganese exposure. Future eﬀorts can reﬁne
the scenarios presented here in humans, examine the eﬀect
of iron homeostasis, and evaluate the eﬀects of particle size
and solubility, including manganese nanoparticles.
A second outcome of these eﬀorts is the increased
conﬁdence in the quantitative predictions of elevated man-
ganese levels that might serve as a basis for a dosimetry-
based risk assessment. An underlying assumption to this
risk assessment approach is that elevated brain manganese
concentration is a prerequisite for the development of
manganese neurotoxicity. From a risk assessor’s perspective,
an upper safe exposure value could be based on an air
concentration that changes brain tissue levels by no more
than some fraction of the normal variability within a
population [7, 72]. While some data gaps still exist regard-
ing the biology of manganese transport and storage, the
models described in this manuscript capture the main dose-
dependent characteristics of manganese disposition. Using a
Monte Carlo analysis to simulate population variability on
targettissuemanganeselevels,modelingsimulationsindicate
that air manganese concentrations of 0.001–0.01mg/m3
are required to begin to inﬂuence natural background
tissue concentrations in adult males, which are the most
sensitivesubgroupregardingmanganesetissueaccumulation
currently examined. With the forthcoming evaluation of
monkey studies of Mn toxicity using the model to assess
dosimetry and with applications to human datasets, the
current PBPK model should be an important compo-
nent of future tissue-dose-based approaches for Mn risk
assessment.
In summary, data collection eﬀorts associated with the
Alternative Tier 2 testing program for MMT over the past
10 to 15 years on tissue Mn after inhalation exposures
at diﬀerent dietary levels and associated PBPK modeling
have greatly improved understanding of the integration of
multiple processes that collectively control Mn concentra-
tions in various tissues. These eﬀorts produced a multidose
route, multispecies PBPK model that recapitulates dose-
dependent brain accumulation on excessive exposures. The
key biological characteristics required in ﬁtting the model
to the rat and monkey tissue time course data were ﬁnite
capacities for tissue binding, slow dissociation of bound Mn,
dose-dependent elimination from liver and dose-dependent
uptake from the diet. As expected with control process for an
essential metal with high-exposure toxicity, the physiological
processespreservebodystoresofMnatlowintakesaccelerate
excretionandreduceoralabsorption athigherintakes. These
dose-dependent processes are well known in a general man-
ner, but not in terms of every biochemical detail. Biological
determinants for tissue binding, membrane transport, Mn
retention in enterocyte and sloughing of these cells into
the intestinal lumen are under investigation. Further detail
regarding these steps will reﬁne speciﬁc parameters in the
current PBPK model. One area ripe for inclusion in the next-
generation PBPK model is increased knowledge of metal
transporters [73–75]. More detailed dose-dependencies for
these transporters would elaborate the asymmetric, dose-
dependent uptake processes into brain in the present model
[76]. However, the relative rate constants cannot vary
signiﬁcantlyfromthecurrentonessincethesimulationswith
the current model show very good correspondence with all
available tissue time-course data. Thus, despite some gaps in
understanding the underlying biology, the PBPK modeling
with Mn shows clearly how similar processes work to control
basal Mn levels to a remarkably common concentration
across species and how they accomplish control of tissue Mn
in the face of widely diﬀerent dietary intake. Controls for
Mn after inhalation include enhanced elimination but lack
the ability to restrict absorption through the lung epithelium
aﬀorded by the gut epithelium for oral ingestion of the
metal.Clearly,thecurrenthumanPBPKmodelstandspoised
to assist in further integration of emerging knowledge into
a more quantitative and biologically complete description
of regulation of Mn in the body. Future work, potentially
including uncertainty and sensitivity analyses, will examine
the inherent limitations of modeling and scaling to help
determine the precise level of conﬁdence that can be
ascribed to the current predictions of human globus pallidus
manganese concentrations. However, in its present form, the
human PBPK model for Mn already provides a solid foun-
dation for improving risk assessment for this essential metal
that also causes neurotoxicity in humans with higher dose
exposures.
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